Jeff was previously the founding CEO of NeuMoDx Molecular, a fully-automated PCR testing solution for today’s modern lab, until its sale to Qiagen NV (QGEN ) for $248M in September 2020. He was also the former President and CEO of Accuri Cytometers, a life science instrument and clinical diagnostic company, until its sale to Becton, Dickinson and Company (NYSE: BDX) for $205M in March 2011. During his tenure at Accuri, Jeff oversaw year-over-year revenue growth of 65%, the development of a clinical system, and the achievement of positive cash flow.
Prior to Accuri, was the President and CEO of HandyLab, a molecular diagnostic company. At HandyLab, Jeff led the growth and venture financing of the company, ultimately resulting in its sale for $275M in November 2009. Prior to HandyLab, Jeff was President and CEO of Genomic Solutions Inc., a life science products company he co-founded in 1997. He led Genomic Solutions through a period of rapid growth culminating in an IPO on NASDAQ in 2000 and merger with Harvard Biosciences, Inc. in late 2002. Prior to Genomic Solutions, Jeff held executive and management level positions in several bioscience companies, including IRIS and Boehringer Mannheim. Jeff received a BS in Biology from Alma College and a MBA from the University of Michigan.